A Prospective Study of Diffusion-weighted Magnetic Resonance Imaging as an Early Prognostic Biomarker in Chemoradiotherapy in Squamous Cell Carcinomas of the Anus.


Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
12 2020
Historique:
received: 13 03 2020
revised: 15 07 2020
accepted: 03 09 2020
pubmed: 8 10 2020
medline: 25 5 2021
entrez: 7 10 2020
Statut: ppublish

Résumé

The use of diffusion-weighted magnetic resonance imaging (DW-MRI) as a prognostic marker of treatment response would enable early individualisation of treatment. We aimed to quantify the changes in mean apparent diffusion coefficient (ΔADC This prospective study recruited patients with localised anal cancer between October 2014 and November 2017. DW-MRI was carried out at diagnosis and after fraction 8-10 of radical CRT. A region of interest was delineated for all primary tumours and any lymph nodes >2 cm on high-resolution T Twenty-three of 29 recruited patients underwent paired DW-MRI scans. Twenty-six regions of interest were delineated among the 23 evaluable patients. The median (range) tumour volume was 13.6 cm We demonstrated a potential correlation between patients with ΔADC

Identifiants

pubmed: 33023818
pii: S0936-6555(20)30364-2
doi: 10.1016/j.clon.2020.09.003
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

874-883

Subventions

Organisme : Medical Research Council
ID : MC_PC_12001/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00001/2
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C5529/A16895
Pays : United Kingdom

Informations de copyright

Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved.

Auteurs

R Muirhead (R)

Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: rebecca.muirhead@oncology.ox.ac.uk.

D Bulte (D)

Institute of Biomedical Engineering, University of Oxford, Oxford, UK.

R Cooke (R)

Radiotherapy Department, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

K-Y Chu (KY)

Radiotherapy Department, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, Oxford, UK.

L Durrant (L)

Radiotherapy Department, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, Oxford, UK.

V Goh (V)

Cancer Imaging, School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK.

C Jacobs (C)

Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

S M Ng (SM)

Oncology Clinical Trials Office, Department of Oncology, University of Oxford, Oxford, UK.

V Y Strauss (VY)

Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.

P S Virdee (PS)

Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.

C Qi (C)

Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.

M A Hawkins (MA)

Radiotherapy Department, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH